Table 3.

Multivariable analysis of all patients with invasive ductal breast cancer (n = 28,590) in the period 2011–2013 per defined outcome modality

Outcome characteristic	MRI use			Primary mastectomy			Margin involvement (more than focal)			Secondary mastectomy			Contralateral breast cancer
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
MRI
No				1 (Ref)			1 (Ref)						1 (Ref)
Yes	N/A			1.30	1.22–1.39	<.0001	0.90	0.77–1.06	0.202	1.23	1.00–1.53	0.054	4.07	3.38–4.90	<.0001
Year of incidence
2011	1 (Ref)			1 (Ref)			1 (Ref)						1 (Ref)
2012	1.02	0.95–1.09	0.629	0.93	0.87–0.99	0.025	0.83	0.71–0.98	0.025	0.84	0.67–1.05	0.122	0.95	0.76–1.18	0.635
2013	1.08	1.01–1.16	0.029	0.93	0.87–1.00	0.047	0.75	0.64–0.89	0.001	0.90	0.72–1.13	0.363	1.14	0.92–1.40	0.242
Age group (years)
70+	1 (Ref)			1 (Ref)			1 (Ref)						1 (Ref)
<50	6.89	6.27–7.56	<.0001	0.63	0.58–0.68	<.0001	1.29	1.05–1.59	0.014	1.94	1.45–2.58	<.0001	0.47	0.35–0.63	<.0001
50−69	2.94	2.70–3.19	<.0001	0.46	0.43–0.49	<.0001	0.82	0.69–0.98	0.027	0.97	0.75–1.25	0.819	0.64	0.52–0.79	<.0001
Clinical tumor size (cT)
cT1	1 (Ref)			1 (Ref)			1 (Ref)						1 (Ref)
cT2	1.66	1.56–1.77	<.0001	3.10	2.87–3.25	<.0001	1.42	1.21–1.68	<.0001	1.29	1.04–1.61	0.023	0.63	0.49–0.81	<.001
cT3–4	3.08	2.57–3.69	<.0001	36.35	25.30–52.23	<.0001	3.61	1.36–9.60	0.010	0.45	0.07–2.98	0.409	0.57	0.26–1.22	0.147
Unknown	0.71	0.61–0.82	<.0001	2.38	2.09–2.69	<.0001	2.59	1.97–3.40	<.0001	2.92	2.04–4.20	<.0001	2.05	1.49–2.82	<.0001
Clinical nodal status (cN)
cN0	1 (Ref)			1 (Ref)			1 (Ref)						1 (Ref)
cN1–3	0.96	0.88–1.05	0.410	2.47	2.26–2.69	<.0001	1.49	1.19–1.86	0.001	1.59	1.18–2.14	0.003	0.82	0.61–1.23	0.423
Unknown	1.02	0.77–1.36	0.880	1.42	1.09–1.86	0.010	1.46	0.79–2.70	0.223	1.43	0.62–3.28	0.400	0.87	0.33–2.03	0.667
ER, PR and HER2 status
ER+ or PR+, and HER2−	1 (Ref)			1 (Ref)			1 (Ref)						1 (Ref)
ER+ or PR+, and HER2+	1.08	0.97–1.19	0.155	1.15	1.04–1.27	0.007	1.36	1.09–1.69	0.006	1.27	0.94–1.71	0.12	0.95	0.66–1.38	0.801
ER− and PR− and HER2−	0.93	0.84–1.03	0.156	1.09	0.99–1.20	0.077	0.72	0.56–0.92	0.009	1.08	0.78–1.49	0.649	0.84	0.56–1.28	0.421
ER− and PR−and HER2+	1.10	0.96–1.27	0.183	1.60	1.39–1.85	<.0001	1.18	0.83–1.67	0.351	2.13	1.40–3.25	0.001	0.45	0.20–1.03	0.057
Unknown	0.88	0.72–1.07	0.195	1.11	0.94–1.31	0.206	0.84	0.56–1.27	0.413	1.52	0.91–2.56	0.114	2.31	1.61–3.32	<.0001
Tumor grade
1	1 (Ref)			1 (Ref)			1 (Ref)						1 (Ref)
2	0.91	0.84–0.97	0.008	1.21	1.13–1.30	<.0001	1.62	1.34–1.95	<.0001	1.91	1.44–2.52	<.0001	0.72	0.59–0.88	0.001
3	0.78	0.71–0.85	<.0001	1.17	1.07–1.27	<.001	1.76	1.42–2.18	<.0001	2.21	1.63–3.01	<.0001	0.35	0.26–0.48	<.0001
Unknown	1.09	0.93–1.28	0.306	1.43	1.22–1.68	<.0001	2.57	1.82–3.62	<.0001	1.72	1.02–2.90	0.043	0.82	0.54–1.24	0.341
Multifocality
No	1 (ref)			1 (Ref)			1 (Ref)						1 (Ref)
Yes	2.62	2.43–2.82	<.0001	4.70	4.34–5.09	<.0001	2.88	2.39–3.47	<.0001	4.41	3.47–5.60	<.0001	0.82	0.63–1.06	0.129
Unknown	0.38	0.25–0.57	<.0001	1.77	1.33–2.34	<.0001	3.15	1.18–8.45	0.023	1.72	0.40–7.37	0.466	0.82	0.37–1.84	0.634
Margin involvement
No
Yes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	45.51	37.69–54.96	<0.0001	N/A	N/A	N/A